

Ref: GLL/BSE/2024-25/Nov -

Date: November 14, 2024

To
The General Manager,
Corporate Relations Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, **Mumbai – 400001**.
Maharashtra State, India.
Script Code: 531739

To
The Listing Manager,
The Ahmedabad Stock Exchange Limited
A-2, Kamdhenu Complex, Opp. Sahajanand
College, 120 Feet Ring Road, Panjara Pol,
Ambawadi, **Ahmedabad - 380015**.
Gujarat State, India.
Script Code:

To
**The Calcutta Stock Exchange
Limited,**
#7, Lyons Range, Murgighata,
Dalhousie, **Kolkata - 700001**,
West Bengal State, India.
Scrip Code: 26178

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting of Gennex Laboratories Limited – Scrip Code:
531739/GENNEX**

Ref: Regulation 29, 33 & 47 of the SEBI (LODR) 'Regulations, 2015.

In just concluded Meeting of Board of Directors, the Board Approved and considered the following items:

1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half year ended September 30, 2024 (annexed herewith);
2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Half year ended September 30, 2024 (annexed here with);
3. Reconstitution of the Audit Committee of the Company;
4. Reconstitution of the Nomination & Remuneration Committee of the Company;
5. Reconstitution of the Stakeholders Relationship Committee of the Company;
6. Appointment of Mr. Akkali Santosh Kumar as Chief Financial Officer of the Company;
7. Other Business items.

We hereby submit that the Board Meeting had commenced at 04:00 PM and concluded at 11:00 PM.

This intimation is also uploaded on the Company website: www.gennexlab.com

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours faithfully,

For Gennex Laboratories Limited

Dinesh Kumar
Kejriwal
Digitally signed by Dinesh
Kumar Kejriwal
Date: 2024.11.14 22:53:55
+05'30'

Dinesh Kumar Kejriwal

Company Secretary & Compliance Officer
Membership #A19293

Gennex Laboratories Limited

Office: 'Akash Ganga' 4th Floor, Plot NO.144, Srinagar colony, Hyderabad-500073, T.S. India | Phone: +91-40-67334400 (30 Lines), Fax: +91-40-67334433
Factory: Sy.No.133, IDA Bollaram, Jinnaram Mandal, Sangareddy Dist – 502325, Telangana, India | Tel: +91-08458 279406, Telefax: +91-08454 279516

Info@gennexlab.com, www.gennexlab.com ■ CIN :L L24230TG1990PLC011168

R Pugalia & Company
Chartered Accountants
20 E Lake Road Kolkata-700029

Limited Review report on Unaudited Consolidated financial results for quarter and half year ended 30th September, 2024 of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.

To
The Board of Directors,
M/s. Gennex Laboratories Limited,
Hyderabad.

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **M/s. Gennex Laboratories Limited** ("the Company") and its share of the net profit/(loss) after tax and total comprehensive income / loss of its Subsidiary for the quarter and half year ended September 30, 2024, and for the period from April 01, 2024 to September 30, 2024 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures corresponding quarter and half year ended September 30, 2024 as reported in these financial results have been approved by the Company's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and In compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of Deccan Remedies Limited. (Subsidiary Company)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of 1 Subsidiary, which have been reviewed by other auditors, whose interim financial results excluding consolidation eliminations reflect total revenues of Rs. 2651.01 Lakhs, total net Profit after tax of Rs. 415.85 Lakhs for the quarter and half year ended September 30, 2024 as considered in the unaudited consolidated financial results. These unaudited financial results and other unaudited financial information have been approved and furnished to us by the management. Our conclusion, in so far as it relates to the affairs of this Subsidiary, is based solely on such unaudited financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For R PUGALIA & COMPANY

Chartered Accountants

Firm Registration No.318188E


RAJEEV KUMAR PUGALIA
Membership No.053972

Place: Kolkata

Date: 14th November 2024

UDIN : 24053972BKCEVM9944



GENNEX LABORATORIES LIMITED
CIN: L24230TG1990PLC011168

REGD. OFF: Survey #133, IDA Bollaram, Jinnaram mandal, Medak District - 502 325, Telanaga State, India.
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER, 2024
Tel. No.+91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

(All amounts in Rs.lakhs except EPES and Ratios)

Statement of Consolidated Unaudited Financial Results for the Quarter and Six months ended September 30, 2024		Quarter Ended			Half Year Ended		Year ended
Sl. No.	Particulars	30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	3,154.89	2,832.18	1,757.94	5,987.07	3,406.78	8,671.44
	(b) Other operating Income	183.13	246.50	59.80	429.63	63.18	490.59
	Total Income from operations (net)	3,338.02	3,078.68	1,817.74	6,416.70	3,469.96	9,162.03
2	Expenses						
	(a) Cost of material consumed	2,088.93	1,802.20	888.54	3,891.13	1,835.13	5,788.05
	(b) Purchases of stock-in-trade						
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-157.80	-22.28	-161.01	-180.08	-606.14	-902.82
	(d) Employee benefit expense	191.71	229.22	233.51	420.93	478.93	779.48
	(e) Finance Cost	111.41	45.29	78.38	156.70	151.37	307.60
	(f) Depreciation and amortisation expense	21.86	73.17	103.45	95.03	168.26	236.78
	(g) Other expenses	469.79	400.22	279.68	870.01	674.95	1,303.76
	Total expenses	2,725.90	2,527.82	1,422.55	5,253.72	2,702.50	7,512.85
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	612.12	550.86	395.19	1,162.98	767.46	1,649.18
4	Exceptional items						
5	Profit(+)/Loss(-) before tax (3+4)	612.12	550.86	395.19	1,162.98	767.46	1,649.18
6	Tax Expenses for earlier years						
7	Current Tax	-75.00	-85.00	-88.64	-160.00	-175.94	-341.00
8	Deferred tax						
9	Total Tax expense	-75.00	-85.00	-88.64	-160.00	-175.94	-331.68
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement						
	Net Profit for the period from continuing operation (5-9)	537.12	465.86	306.55	1,002.98	591.52	1,317.50
12	Total profit(loss) for period	537.12	465.86	306.55	1,002.98	591.52	1,317.50
13	Other comprehensive Income net of taxes						180.23
14	Net profit(loss) for period	537.12	465.86	306.55	1,002.98	591.52	1,137.27
15	Profit Attributable to :						
	Owners of the parent	482.60	436.84	286.65	919.43	558.02	1,232.39
	Non Controlling Interest	54.52	29.02	19.90	83.55	33.50	85.11
15	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	2,274.47	2,274.47	1,766.43	2,274.47	1,766.43	2,274.47
16	Other Equity						
	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) (of Rs. 1 each) (not annualised) :						
	(a) Basic	0.21	0.19	0.16	0.40	0.32	0.54
	(b) Diluted	0.21	0.19	0.16	0.40	0.33	0.61

Consolidated Notes:

- The statement of Consolidated unaudited financial results of the Company for the Quarter and Half-Year ended September 30, 2024, has been reviewed by the Audit Committee and approved by the Board of Directors on November 14, 2024. These have been reviewed by the R Pugalia & Co., the Statutory Auditor of the Company, who have issued an unmodified qualified review report.
- The Consolidated unaudited financial results of Gennex Laboratories Limited ('the Company') have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 'Interim Financial Reporting' Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act 2013 ('the Act'), read with the Companies (Indian Accounting Standard) Rule, 2015, as amended from time to time and other accounting principles generally accepted in India.
- The Company operating segment is "Bulk Drugs" Manufacturing as its deals mainly with Guaifenesin, Methocarbamol, it also does business outside India. The Company operates in single segment and therefore the Segment Reporting as per AS-17 is not applicable for the Company.
- Previous period's figures have been rearranged / regrouped wherever necessary
- The quarterly unaudited Consolidated Financial results for the Quarter and Half Year ended September 30, 2024 are available on the Company's Website i.e., www.gennexlab.com and also available on BSE website i.e., www.bseindia.com.

For Gennex Laboratories Limited

Date: 14.11.2024
Place: Hyderabad



Arihant Baid
Managing Director

Arihan
t Baid
Digitally signed
by Arihant Baid
Date: 2024.11.14
23:07:43 +05'30'

**GENNEX LABORATORIES LIMITED****Statement of Assets and Liabilities - Consolidated****(Rs. in lakhs)**

Particulars	As at September 30,2024	As at March 31,2024
	Unaudited	Audited
B) ASSETS		
1 Non-Current Assets		
a) Tangible Assets	6,401.18	6,410.87
b) Intangible Assets	294.06	294.06
c) Non-Current Investments	1.00	1.00
d) Long-term loans and advances	111.23	111.23
Sub-total Non-current assets	6,807.47	6,817.16
2 Current Assets		
a) Current Investments		-
b) Inventories	4,015.90	2,517.50
c) Trade receivable	2,599.47	1,781.11
d) Cash and Cash equivalents	5,253.74	6,097.49
e) Short-term loans and advances	5,420.62	5,529.38
f) Other current assets	332.73	255.93
Sub-total - Current assets	17,622.46	16,181.41
TOTAL - ASSETS	24,429.93	22,998.57
A) EQUITY AND LIABILITIES		
1 Shareholders' Funds:		
a) Share Capital	2,274.47	2,274.47
b) Equity Warrants	571.95	571.95
c) Reserves and Surplus	15,194.70	14,191.72
d) Non Controlling Interest NET	608.31	608.31
Sub-total Shareholders' Fund	18,649.43	17,646.45
2 Non - Current Liabilities		
a) Long-term borrowings	1,613.43	1,321.64
Sub-total Non-current liabilities	1,613.43	1,321.64
3 Current Liabilities		
a) Short-term borrowings	1,319.12	572.05
b) Trade payables	1,588.40	1,518.03
c) Other current liabilities	408.00	1,369.16
d) Short-term provisions	851.55	571.24
Sub-total Current liabilities	4,167.07	4,030.48
TOTAL EQUITY AND LIABILITIES	24,429.93	22,998.57

Date: 14.11.2024
Place: Hyderabad**For Gennex Laboratories Limited**Digitally signed by
Arihant Baid
Date: 2024.11.14 23:08:05
+05'30'
Arihant Baid
Managing Director

**GENNEX LABORATORIES LIMITED****CONSOLIDATED CASH FLOW STATEMENT AS ON 30TH SEPTEMBER, 2024**

	30-09-2024	31-03-2024
	(Rs. In Lacs)	(Rs. In Lacs)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before Tax	1002.97	1649.18
Adjustment for :		
Depreciation and amoratisation expense	95.03	236.79
Finance Cost	156.70	307.60
Interest Income	403.56	-379.48
Operating Profit before working capital changes	1658.26	1814.09
Adjustment for :		
Trade payables and other liability	70.37	204.99
Other Financial Liability	-680.85	
Trade receivables	-818.36	-839.46
Inventories	-1498.40	-948.25
Financial and other Assets	31.96	-4900.01
Cash generated from operations	-1237.02	-4668.64
Adjustments for :		
Income Taxes paid	0.00	0.00
Net Cash from operating activities	-1237.02	-4668.64
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	-85.34	0.00
Sale of property, plant and equipment		1535.30
Increase in Security Deposit		-23.44
Interest Income	-403.56	379.48
Finance Cost	-156.70	
Net Cash used in Investing activities	-645.60	1891.34
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of Capital	0.00	7983.15
Proceeds from others		
Changes in Long Term Borrowings	291.79	-307.17
Changes in Short Term Borrowings (Net)	747.07	0.00
Interest Paid & Finance cost		-307.60
Net Cash from Financing activities	1038.86	7368.38
Net Increase / (Decrease) in Cash and Cash equivalent (A+B+C)	-843.76	4591.08
Cash and Cash Equivalents as at the beginning of the year	6097.50	1506.42
Cash and Cash Equivalents as at the end of the year	5253.74	6097.50
Notes:		
1. The above Cash Flow Statement has been prepared under the " Indirect Method" set out in Indian Accounting Standard (Ind-AS)- 7 on Statement of Cash Flow.		
2. Figures in bracket indicate cash outflow.		
3. Previous year comparatives have been reclassified to confirm with current year's presentation, wherever applicable.		

Date : 14-11-2024
Place: Hyderabad



For and on behalf of the Board

Arihant Baid

Digitally signed by
Arihant Baid
Date: 2024.11.14
23:08:27 +05'30'

Arihant Baid
Managing Director

R Pugalia & Company
Chartered Accountants
20 E Lake Road Kolkata-700029

Limited Review report on Unaudited Standalone financial results for quarter and half year ended 30th September, 2024 of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.

To
The Board of Directors,
M/s. Gennex Laboratories Limited,
Hyderabad.

We have reviewed the accompanying Statement of Unaudited Standalone financial results of **Gennex Laboratories Limited** for the Quarter and half year ended September 30, 2024 and for the period from April 01, 2024 to September 30, 2024 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliances with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention, except as stated below, that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



For R PUGALIA & COMPANY
Chartered Accountants
Firm Registration No.318188E



RAJEEV KUMAR PUGALIA
Membership No. 053972

Place: Kolkata

Date: 14th November 2024

UDIN : 24053972BKCEVI1905



GENNEX LABORATORIES LIMITED
CIN: L24230TG1990PLC011168

REGD. OFF: Survey #133, IDA Bollaram, Jinnaram mandal, Medak District - 502 325, Telangana State, India.
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER, 2024
Tel. No. +91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

(All amounts in Rs.lakhs except EPES and Ratios)

Statement of Standalone Unaudited Financial Results for the Quarter and Six months ended September 30, 2024							(Rs. in lakhs)
Sl. No.	Particulars	Quarter Ended			Half Year Ended		Year ended
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	2,468.59	2,133.40	1,424.45	4,601.99	2,838.91	6,679.87
	(b) Other operating Income	182.42	245.93	5.88	428.35	9.26	430.20
	Total Income from operations (net)	2,651.01	2,379.33	1,430.33	5,030.34	2,848.17	7,110.07
2	Expenses						
	(a) Cost of material consumed	1,388.84	1,118.87	680.18	2,507.71	1,543.00	4,087.77
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	216.07	213.15	-17.97	429.22	-328.76	-243.75
	(d) Employee benefit expense	149.20	190.43	177.57	339.63	361.75	604.65
	(e) Finance Cost	46.97	17.18	28.16	64.15	58.47	115.57
	(f) Depreciation and amortisation expense	5.21	29.49	20.27	34.70	40.50	81.04
	(g) Other expenses	343.87	318.61	187.54	662.48	474.11	989.31
	Total expenses	2,150.16	1,887.72	1,075.76	4,037.89	2,149.07	5,634.59
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	500.85	491.61	354.57	992.45	699.09	1,475.48
4	Exceptional items	-	-	-	-	-	-
5	Profit(+)/Loss(-) before tax (3+4)	500.85	491.61	354.57	992.45	699.09	1,475.48
6	Tax Expenses for earlier years	-	-	-	-	-	-
7	Current Tax	-85.00	-75.00	-88.64	-160.00	-175.94	-305.00
8	Deferred tax	-	-	-	-	-	9.32
9	Total Tax expense	-85.00	-75.00	-88.64	-160.00	-175.94	-295.68
10	Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	-	-	-	-	-	-
11	Net Profit for the period from continuing operation (5-9)	415.85	416.61	265.93	832.45	523.15	1,179.80
12	Profit(+)/Loss(-) from discontinued operations before tax	-	-	-	-	-	-
13	Tax expense of discontinued operations	-	-	-	-	-	-
14	Net Profit(loss) for the period from discontinued operations	-	-	-	-	-	-
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	-	-	-	-	-	-
16	Total profit(loss) for period	415.85	416.61	265.93	832.45	523.15	1,179.80
17	Other comprehensive income net of taxes	-	-	-	-	-	11.05
18	Net profit(loss) for period	415.85	416.61	265.93	832.45	523.15	1,190.85
19	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	2,274.47	2,274.47	1,766.43	2,274.47	1,766.43	2,274.47
20	Other Equity	-	-	-	-	-	-
	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) (of Rs. 1 each) (not annualised) :						
	(a) Basic	0.18	0.18	0.15	0.37	0.30	0.524
	(b) Diluted	0.18	0.18	0.15	0.37	0.30	0.524

Standalone Notes:

- The statement of Standalone unaudited financial results of the Company for the Quarter and Half-Year ended September 30, 2024, has been reviewed by the Audit Committee and approved by the Board of Directors on November 14, 2024. These have been reviewed by the R Pugalia & Co., the Statutory Auditor of the Company, who have issued an unmodified qualified review report.
- The standalone unaudited financial results of Gennex Laboratories Limited ('the Company') have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 'Interim Financial Reporting' Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act 2013 ('the Act'), read with the Companies (Indian Accounting Standard) Rule, 2015, as amended from time to time and other accounting principles generally accepted in India.
- The Company operating segment is "Bulk Drugs" Manufacturing as its deals mainly with Guaifenesin, Methocarbamol, it also does business outside India. The Company operates in single segment and therefore the Segment Reporting as per AS-17 is not applicable for the Company.
- Previous period's figures have been rearranged / regrouped wherever necessary
- The quarterly unaudited standalone Financial results for the Quarter and Half Year ended September 30, 2024 are available on the Company's Website i.e., www.gennexlab.com and also available on BSE website i.e., www.bseindia.com.

For Gennex Laboratories Limited

Date: 14.11.2024
Place: Hyderabad



Arihant Baid
Managing Director

Arihan
t Baid
Digitally signed
by Arihant Baid
Date:
2024.11.14
23:05:21 +05'30'

**GENNEX LABORATORIES LIMITED****Statement of Assets and Liabilities - Standalone****(Rs. in lakhs)**

Particulars	As at September 30,2024	As at March 31,2024
	Unaudited	Audited
B) ASSETS		
1 Non-Current Assets		
a) Tangible Assets	1,595.06	1,582.81
b) Intangible Assets	161.05	161.05
c) Non-Current Investments	826.42	826.42
d) Long-term loans and advances	11.62	64.26
Sub-total Non-current assets	2,594.15	2,634.54
2 Current Assets		
a) Current Investments		-
b) Inventories	2,120.87	1,607.25
c) Trade receivable	2,520.93	1,356.78
d) Cash and Cash equivalents	5,217.07	6,096.19
e) Short-term loans and advances	8,889.26	8,622.76
f) Other current assets	124.30	216.29
Sub-total - Current assets	18,872.43	17,899.27
TOTAL - ASSETS	21,466.58	20,533.81
A) EQUITY AND LIABILITIES		
1 Shareholders' Funds:		
a) Share Capital	2,274.47	2,274.47
b) Equity Warrants	571.95	571.95
c) Reserves and Surplus	15,061.96	14,229.51
Sub-total Shareholders' Fund	17,908.38	17,075.93
2 Non - Current Liabilities		
a) Long-term borrowings	318.16	175.81
Sub-total Non-current liabilities	318.16	175.81
3 Current Liabilities		
a) Short-term borrowings	895.92	84.72
b) Trade payables	1,270.76	1,435.12
c) Other current liabilities	407.99	1,226.99
d) Short-term provisions	665.37	535.24
Sub-total Current liabilities	3,240.04	3,282.07
TOTAL EQUITY AND LIABILITIES	21,466.58	20,533.81

Date: 14.11.2024
Place: Hyderabad**For Gennex Laboratories Limited**Arihant Baid
Arihant Baid
Managing DirectorDigitally signed by
Arihant Baid
Date: 2024.11.14 23:05:50
+0530

**GENNEX LABORATORIES LIMITED****STANDALONE CASH FLOW STATEMENT AS ON 30 SEP 2024**

	30.09.2024 (Rs. In Lacs)	31-03-2024 (Rs. In Lacs)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit after Tax	832.46	1486.53
Adjustment for :		
Depreciation and amoratisation expense	34.70	81.04
Finance Cost	64.15	115.58
Interest Income	-403.51	-376.94
(Gain)/loss on sale of asset	0	0.00
	0.00	
Operating Profit before working capital changes	527.80	1306.20
Adjustment for :		
Trade payables and other liability	-164.36	785.99
Trade receivables	-1164.15	-474.69
Inventories	-513.62	-110.00
Financial and other Assets	-121.87	-5463.55
Other Current Liabilities	-688.87	722.40
Cash generated from operations	-2125.07	-3233.65
Income Taxes paid		-109.14
Net Cash from operating activities	-2125.07	-3342.79
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property,plant and equipment	-46.94	-284.22
Sale of property,plant and equipment	0.00	0.00
Purchase of Equity Shares	0.00	0.00
Interest Income	403.51	376.94
Net Cash in Investing activities	356.57	92.72
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of Capital	0.00	7983.15
Changes in Long Term Borrowings	142.35	47.00
Changes in Short Term Borrowings (Net)	811.20	-13.44
Interest Paid	-64.16	-115.58
Net Cash from Financing activities	889.39	7901.13
Net Increase / (Decrease) in Cash and Cash equivalent (A+B+C)	-879.11	4651.06
Cash and Cash Equivalent as at the beginning of the year	6096.19	1445.13
Cash and Cash Equivalent as at the end of the year	5217.08	6096.19
Notes:		
1. The above Cash Flow Statement has been prepared under the " Indirect Method" set out in Indian Accounting Standard (Ind-AS)- 7 on Statement of Cash Flow.		
2. Figures in bracket indicate cash outflow.		
3. Previous year comparatives have been reclassified to confirm with current year's presentation,wherever applicable.		

Place : Hyderabad
Date : 14 Nov 2024



For and on behalf of the Board

Arihant Baid
Digitally signed by Arihant Baid
Date: 2024.11.14 23:06:25 +0530
Arihant Baid
Managing Director